M. Urashima et al., CHARACTERIZATION OF P16(INK4A) EXPRESSION IN MULTIPLE-MYELOMA AND PLASMA-CELL LEUKEMIA, Clinical cancer research, 3(11), 1997, pp. 2173-2179
Loss of pl6(INK4A) (p16) expression is frequently associated with the
development of epithelial and lymphoid malignancies, However, the freq
uency and significance of p16 abnormalities in multiple myeloma (MM) a
nd the more aggressive phase of plasma cell leukemia (PCL) have not be
en well defined, Accordingly, the goal of this study was to define the
expression and function of p16 in fresh samples of MM and PCL, We fou
nd that p16 protein was highly expressed in primary MM cells, although
it was undetectable in fresh samples of PCL. Additionally, p16 protei
n was also absent in four of four MM-derived cell lines, To determine
the mechanism for p16 underexpression in PCL and MM-derived cell lines
, we performed PCR analysis to evaluate both gene deletion and the pre
sence of methylation, Interestingly, the p16 gene was present and meth
ylated in all patient PCL cells and MM cell lines, whereas it was unme
thylated in patient MM cells and normal B cells, Furthermore, treatmen
t with the demethylating agent 5-deoxyazacytidine or p16 retrofection
restored p16 protein expression and induced G(1), growth arrest in pat
ient PCL cells and MM cell lines, These results suggest that inactivat
ion of the p16 gene by methylation may be associated with decreased gr
owth control and the development of PCL in a subset of patients with M
M.